Overall, these findings suggest that acetylated KIAA1429-mediated m6A modification endows HCC cells with immune evasion through regulation of KDM5B/FoxO1 axis, which provide a treatment option for HCC by targeting KIAA1429. This evidence concerns the gene VIRMA and hepatocellular carcinoma.